Illumina (ILMN)
Illumina is improving human health by unlocking the power of the genome. Its focus on innovation has established it as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. The Company products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.
Company profile
Ticker
ILMN
Exchange
Website
CEO
Francis deSouza
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Agilent • Perkinelmer • Bio-Rad Laboratories • Waters • Avantor • Mettler-Toledo International • Bruker • Coherent • Seer • Cue Health ...
Former names
ILLUMINA INC
SEC CIK
Corporate docs
Subsidiaries
Advanced Liquid Logic Inc. • BlueBee Belgium BVBA • BlueBee Holding BV • BlueGnome, Ltd. • Conexio Genomics Pty Ltd. • Emedgene Technologies Ltd • Emedgene, Inc. • Enancio SAS • GRAIL, LLC • Illumina AB ...
IRS number
330804655
ILMN stock data
Press releases
GRAIL and Intermountain Healthcare Expand Partnership to Offer Galleri® Multi-Cancer Early Detection Blood Test to Eligible Patients in Utah
17 May 22
Comprehensive Study Establishes Cost of Late Detection and Treatment of Cancer
12 May 22
Illumina and Deerfield Management partner to accelerate drug development
5 May 22
Thinking about trading options or stock in Illumina, Progressive, Apple, Wayfair, or Marathon Petroleum?
3 May 22
Illumina To Webcast Upcoming Investor Conference
28 Apr 22
Analyst ratings and price targets
Current price
Average target
$345.00
Low target
$325.00
High target
$360.00
Piper Sandler
Maintains
$360.00
Morgan Stanley
Maintains
$350.00
Citigroup
Maintains
$325.00
Calendar
4 May 22
17 May 22
1 Jan 23
Financial summary
| Quarter (USD) | Apr 22 | Jan 22 | Oct 21 | Jul 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Jan 22 | Jan 21 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 1.35B | 1.35B | 1.35B | 1.35B | 1.35B | 1.35B |
| Cash burn (monthly) | (no burn) | 256.83M | (no burn) | 5.67M | (no burn) | (no burn) |
| Cash used (since last report) | n/a | 377.38M | n/a | 8.33M | n/a | n/a |
| Cash remaining | n/a | 973.62M | n/a | 1.34B | n/a | n/a |
| Runway (months of cash) | n/a | 3.8 | n/a | 236.9 | n/a | n/a |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 5 May 22 | John Edward Frank | Common Stock | Grant | Acquire A | No | No | 0 | 1,714 | 0 | 1,714 |
| 5 May 22 | John Edward Frank | Performance Shares Common Stock | Grant | Acquire A | No | No | 0 | 5,142 | 0 | 5,142 |
| 5 May 22 | Jose Torres | Common Stock | Payment of exercise | Dispose F | No | No | 291.72 | 69 | 20.13K | 1,748 |
| 28 Apr 22 | Charles Dadswell | Common Stock | Sell | Dispose S | Yes | Yes | 300.13 | 368 | 110.45K | 7,427 |
| 12 Apr 22 | Hoyt Aimee L | Common Stock | Sell | Dispose S | No | Yes | 355.38 | 100 | 35.54K | 5,342 |
| 12 Apr 22 | Hoyt Aimee L | Common Stock | Sell | Dispose S | No | Yes | 352.82 | 1,553 | 547.93K | 5,442 |
| 12 Apr 22 | Hoyt Aimee L | Common Stock | Sell | Dispose S | No | Yes | 349.46 | 300 | 104.84K | 6,995 |
| 12 Apr 22 | Hoyt Aimee L | Common Stock | Sell | Dispose S | No | Yes | 346.25 | 100 | 34.63K | 7,295 |
| 12 Apr 22 | Hoyt Aimee L | Common Stock | Sell | Dispose S | No | Yes | 344.78 | 121 | 41.72K | 7,395 |
| 12 Apr 22 | Hoyt Aimee L | Common Stock | Sell | Dispose S | No | Yes | 342.98 | 100 | 34.3K | 7,516 |
Institutional ownership, Q4 2021
89.8% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 1035 |
| Opened positions | 120 |
| Closed positions | 137 |
| Increased positions | 424 |
| Reduced positions | 333 |
| 13F shares | Current |
|---|---|
| Total value | 53.12B |
| Total shares | 141.11M |
| Total puts | 1.46M |
| Total calls | 1.32M |
| Total put/call ratio | 1.1 |
| Largest owners | Shares | Value |
|---|---|---|
| Baillie Gifford & Co | 20.48M | $7.79B |
| Vanguard | 12.2M | $4.64B |
| BLK Blackrock | 11.78M | $4.48B |
| Edgewood Management | 8.74M | $3.33B |
| STT State Street | 6.4M | $2.44B |
| Growth Fund Of America | 4.99M | $1.5B |
| BK Bank Of New York Mellon | 3.96M | $1.5B |
| Loomis Sayles & Co L P | 3.6M | $1.37B |
| Wellington Management | 3.18M | $1.21B |
| Polen Capital Management | 2.66M | $1.01B |
Financial report summary
?Competition
Thermo Fisher Scientific • Roche Holding • Luminex • Biocept • Agilent • HTG Molecular Diagnostics • Caredx • Opgen • Pacific Biosciences of California • Vyant BioContent analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. freshman Good
|
|
New words:
armed, began, bifurcated, billing, Circuit, civil, claim, classified, comprised, conflict, correlation, coupon, denial, direct, enterprise, exceeded, extent, feature, GILTI, host, incentive, inequitable, judge, jury, kind, negative, negatively, opening, original, oversight, political, professional, proposed, PSU, recognition, reimburse, removed, rendered, repealed, Reply, respond, restate, retained, retroactively, retrospective, Russia, Russian, ship, slightly, Specifically, spillover, Ukraine, unamortized, unknown, upheld, verdict, willfully
Removed:
anniversary, anticipation, assumption, Bank, beneficiary, broker, commitment, consolidate, consummating, contractually, curve, dealer, delay, divest, earlier, EPS, event, exceed, facilitating, failure, favorable, fee, funded, funding, Goldman, hold, identical, implied, indirectly, letter, loan, met, monthly, narrow, observable, offered, ownership, participate, purported, purpose, Realized, represented, Reverse, set, structured, unconsolidated, USA, valuation, vest, VIE, yield
Financial reports
Current reports
8-K
Other Events
6 May 22
8-K
Illumina Reports Financial Results for First Quarter of Fiscal Year 2022
4 May 22
8-K
Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2021
10 Feb 22
8-K
Results of Operations and Financial Condition
11 Jan 22
8-K
Illumina Reports Financial Results for Third Quarter of Fiscal Year 2021
4 Nov 21
8-K/A
Grail Audited Consolidated Financial Statements As of and for the Years
28 Oct 21
8-K
Illumina Appoints Bob Ragusa as Chief Executive Officer (CEO) of GRAIL
14 Oct 21
8-K
Illumina Acquires GRAIL to Accelerate Patient Access to Life-Saving Multi-Cancer Early-Detection Test
18 Aug 21
8-K
Illumina Reports Financial Results for Second Quarter of Fiscal Year 2021
5 Aug 21
8-K
Submission of Matters to a Vote of Security Holders
27 May 21
Registration and prospectus
SC TO-I/A
Issuer tender offer statement (amended)
21 Dec 21
SC TO-I/A
Issuer tender offer statement (amended)
22 Nov 21
SC TO-I
Issuer tender offer statement
15 Nov 21
425
Business combination disclosure
12 Aug 21
425
Business combination disclosure
6 Aug 21
425
Business combination disclosure
5 Aug 21
425
Business combination disclosure
22 Jul 21
425
Business combination disclosure
7 Jul 21
425
Business combination disclosure
21 Jun 21
425
Business combination disclosure
17 Jun 21
Proxies
DEFR14A
Revised proxy
20 Apr 22
DEFA14A
Additional proxy soliciting materials
14 Apr 22
PRE 14A
Preliminary proxy
28 Mar 22
DEFA14A
Additional proxy soliciting materials
16 Apr 21
DEFA14A
Additional proxy soliciting materials
16 Apr 20
DEF 14A
Definitive proxy
16 Apr 20
DEFA14A
Additional proxy soliciting materials
24 May 19
DEFA14A
Additional proxy soliciting materials
16 Apr 19
Other
CORRESP
Correspondence with SEC
21 Nov 21
UPLOAD
Letter from SEC
18 Nov 21
SD
Conflict minerals disclosure
19 May 21
EFFECT
Notice of effectiveness
10 Feb 21
CORRESP
Correspondence with SEC
4 Feb 21
UPLOAD
Letter from SEC
2 Dec 20
SD
Conflict minerals disclosure
20 May 20
SD
Conflict minerals disclosure
13 May 19
SD
Conflict minerals disclosure
30 May 18
CT ORDER
Confidential treatment order
8 Mar 18
Ownership
4
ILLUMINA / JOSE TORRES ownership change
9 May 22
4
ILLUMINA / John Edward Frank ownership change
9 May 22
4
ILLUMINA / Charles Dadswell ownership change
2 May 22
3
ILLUMINA / John Edward Frank ownership change
21 Apr 22
4
ILLUMINA / Aimee L Hoyt ownership change
14 Apr 22
4
ILLUMINA / Kevin Carl Pegels ownership change
7 Apr 22
4
ILLUMINA / Phillip G. Febbo ownership change
7 Apr 22
4
ILLUMINA / Carissa Rollins ownership change
7 Apr 22
4
ILLUMINA / Charles Dadswell ownership change
30 Mar 22
3
ILLUMINA / Carissa Rollins ownership change
21 Mar 22
Patents
Utility
Sensor and sensing system
17 May 22
A sensor includes two electrodes and a modulatable electrically conductive channel attached to the two electrodes.
Utility
Self assembled patterning using patterned hydrophobic surfaces
17 May 22
Embodiments provided herewith are directed to self-assembled methods of preparing a patterned surface for sequencing applications including, for example, a patterned flow cell or a patterned surface for digital fluidic devices.
Utility
Detector with reduced fluorescence range noise
17 May 22
There is set forth herein a device comprising structure defining a detector surface configured for supporting biological or chemical substances, and a sensor array comprising light sensors and circuitry to transmit data signals using photons detected by the light sensors.
Utility
Detecting Materials In a Mixture Using Oligonucleotides
12 May 22
A method of detecting materials in a mixture of materials may include providing materials, and providing oligonucleotides having different sequences than one another.
Utility
On-flow Cell Three Dimensional Polymer Structures
12 May 22
A method for making on-flow cell three-dimensional polymer structures includes loading a polymer precursor solution onto a flow cell.
Transcripts
2022 Q1
Earnings call transcript
6 May 22
2021 Q4
Earnings call transcript
11 Feb 22
2021 Q3
Earnings call transcript
5 Nov 21
2021 Q2
Earnings call transcript
6 Aug 21
2021 Q1
Earnings call transcript
28 Apr 21
2020 Q4
Earnings call transcript
12 Feb 21
2020 Q3
Earnings call transcript
29 Oct 20
2020 Q2
Earnings call transcript
7 Aug 20
2020 Q1
Earnings call transcript
30 Apr 20
2019 Q4
Earnings call transcript
29 Jan 20
Reddit threads
Anybody else just buying MSFT?
15 May 22
Do non-penny stocks that drop into penny stock status ever climb back to or exceed their previous ATH?
10 May 22
Market close - Monday, May 9 2022 🔻🩸🔴
9 May 22
Daily Discussion Thread - May 5th, 2022
5 May 22
Daily Discussion Thread - May 4th, 2022
4 May 22
Followup- Here are the results so far from my algo's price calculations on the symbols you gave me:
28 Apr 22
Why I’m long on long read DNA sequencing ($PACB, LON:$ONT)
28 Apr 22
Name a stock, and ilk tell you the fair price per share.
27 Apr 22
Elon's next company will start with the letter i
27 Apr 22
What are your purchases this past week?
23 Apr 22